Pharmaceutical Pricing and Reimbursement Policies: lessons learnt and perspectives for Brazil
The special series “Pharmaceutical Pricing and Reimbursement Policies” published throughout 2022, was organised by invitation of the Brazilian Journal of Hospital Pharmacy and Health Services, to characterise medicines pricing and reimbursement in Brazil and other countries and discuss implementation, effects, gaps and opportunities for improvement. The series included an editorial, a perspective on the Pharmaceutical Pricing and Reimbursement Policies (PPRI) network and eight country case studies, namely Austria, Brazil, Greece, Canada, Italy, United Kingdom, Portugal and the United States. In closing the series, an overview is presented, as well as a critical appraisal of how aspects such as innovation, access, health litigation, the importance of international cooperation and networking are producing advances or setbacks for country pharmaceutical regulation, pricing and reimbursement, and in-place health technology assessment. This article also highlights the scenario in Brazil, with recent developments in pharmaceutical policies approaching medicines pricing, incorporation (reimbursement), access, and expenditure, at the same time introducing arguments that show how these same issues may intertwine with planning and budgets, straining sustainability and threatening the concept of comprehensiveness adopted by the Unified Health System. New perspectives for strengthening of pharmaceutical regulation, pricing and reimbursement policies with a life-cycle approach, aiming for improving access to essential medicines, stimulating innovation and ensuring sustainability of the health system are needed. Experiences in the series´ case studies are examples of benchmarking and best practices, opportunities for increasing collaboration and sources of inspiration.
Ivama-Brummell AM, Pingret-Kipman D, Osorio-de-Castro CS, et al. Medicines pricing and reimbursement: innovation, competitiveness, and access. Rev Bras Farm Hosp Serv Saud. 2022;1–5. DOI: 10.30968/rbfhss.2022.131.0679.
Vogler S. Pharmaceutical regulation and policies in Austria. Rev Bras Farm Hosp e Serv Saúde. 2022;13(1):639–639. DOI: 10.30968/rbfhss.2022.131.0639.
Ivama-Brummell AM, Pingret-Kipman D, Louly PG, et al. Medicines regulation, pricing and reimbursement in Brazil. Rev Bras Farmácia Hosp e Serviços Saúde. 2022;13(1):769. DOI: 10.30968/rbfhss.2022.131.0769.
Bonnet C, Stafinski T, Trindade E. Medicines pricing and reimbursement in Canada. Rev Bras Farmácia Hosp e Serviços Saúde. 2022;13(2):811–811. DOI: 10.30968/rbfhss.2022.132.0811.
Barbosa MM, Zampirolli CD, Zuppo IF, et al. Regulatory intelligence of health technologies in Greece. Rev Bras Farm Hosp e Serv Saúde. 2022;13(1):789–789. DOI: 10.30968/rbfhss.2022.131.0789.
Melo VA, Ascef BO, Gianfrate F. Italy – a study case of medicines pricing and reimbursement. Rev Bras Farm Hosp e Serv Saúde. 2022;13(2):814–814. DOI: 10.30968/rbfhss.2022.132.0814.
Caldeira S, Pingret-Kipman D, Ferrador F, et al. Health Technology Assessment in Portugal: health policies, methodologies and emerging challenges. Rev Bras Farm Hosp Ser Saúde. 2022;13(3):861–861. DOI: 10.30968/rbfhss.2022.133.0861.
Ivama-Brummell AM, Pinilla-Dominguez P, Biz AN. The regulatory, evaluation, pricing and reimbursement pathway for medicines in the UK: combining innovation and access. Rev Bras Farm Hosp Serviços Saúde. 2022;13(2):804. DOI: 10.30968/rbfhss.2022.132.0804.
Socal MP, Ortiz JA, Garcia F, et al. Pharmaceutical regulation, pricing, coverage and policy reform in the United States of America. Rev Bras Farmácia Hosp e Serv Saúde. 2022;13(3):847–847. DOI: 10.30968/rbfhss.133.0847.
Vogler S, Zimmermann N. Improving medicines access in Brazil through collaboration in the PPRI network. Rev Bras Farmácia Hosp e Serviços Saúde. 2022;13(2):677–677. DOI: 10.30968/rbfhss.2022.132.0677.
World Health Organisation (WHO). Resolution WHA 72(8) Improving the transparency of markets for medicines, vaccines, and other health products. 2019.
Vogler S, Paris V, Panteli D. Ensuring access to medicines: How to redesign pricing, reimbursement and procurement? In: Mossialos E, editor. Addressing Policy Fail Pharm Ser. 2018.
World Health Organisation (WHO). WHO Guideline on Country Pharmaceutical Pricing Policies. Geneva; 2020.
Panteli D, Edwards S. Ensuring access to medicines: How to stimulate innovation to meet patients’ needs? Policy Brief 29. Mossialos E, editor. Denmark: WHO Regional Office for Europe; 2018.
World Health Organization (WHO). Towards access 2030: WHO essential medicines and health products strategic framework 2016-2030. Geneva; 2017.
Pan American Health Organization/World Health Organization (PAHO/WHO). Essential public health functions. Accessed on: 14 Dec 2022. Available in: https://www.paho.org/en/topics/essential-public-health-functions.
Gadelha CAG, Temporão JG. Development, innovation and health: The theoretical and political perspective of the health economic-industrial complex. Cienc e Saude Coletiva. 2018;23(6):1891–1902. DOI: 10.1590/1413-81232018236.06482018.
Associação Brasileira de Saúde Coletiva (Abrasco). Controle de preços dos medicamentos é responsabilidade sanitária - ABRASCO. Accessed on: 3 Nov 2021. Available in: https://www.abrasco.org.br/site/noticias/institucional/controle--de-precos-dos-medicamentos-e-responsabilidade-sanitaria/61733/.
Instituto de Defesa do Consumidor (IDEC). Meio cheio ou meio vazio? Rev do Idec. São Paulo; 2010;22–25.
Conselho Nacional de Saúde. RECOMENDAÇÃO No 030, DE 22 DE SETEMBRO DE 2021. Accessed on: 25 Sep 2021. Avai lable in: http://conselho.saude.gov.br/recomendacoes-cns/2039-recomendacao-n-030-de-22-de-setembro-de-2021.
Dias LL dos S, Santos MAB dos, Pinto CDBS. Regulação contemporânea de preços de medicamentos no Brasil – uma análise crítica. Saúde em Debate. 2019;43(121):543–558. DOI: 10.1590/0103-1104201912120.
Brasil. Ministério da Economia. Conselho de Monitoramento e Avaliação de Políticas Públicas (CMAP). Relatório de Avaliação do Componente Especializado da Assistência Farmacêutica (CEAF). Portal da Saúde. 2019.
Safatle L. Preços de medicamentos e a necessidade de uma abordagem que vá além das questões regulatórias | CEE Fiocruz. Centro de Estudos Estratégicos da Fiocriz Antonio Ivo de Carvalho. 2021 Accessed on: 26 Oct 2022. Available in: https://cee.fiocruz.br/?q=Leandro-Safatle&utm_source=CEE+Fiocruz&utm_campaign=807c49d52e-EMAIL_CAMPAIGN_2022_10_21_03_03&utm_medium=email&utm_term=0_280788378a-807c49d52e-40877633.
Fonseca EM da, Shadlen KC, Bastos FI. The politics of COVID-19 vaccination in middle-income countries: Lessons from Brazil. Soc Sci Med. Pergamon; 2021;281:114093. DOI: 10.1016/J.SOCSCIMED.2021.114093.
Organisation for Economic Cooperation and Development (OECD). Health resources - Pharmaceutical spending – OECD Data. Accessed on: 12 Dec 2022. Available in: https://data.oecd.org/healthres/pharmaceutical-spending.htm.
Brasil. Ministério da Saúde. Fundação Oswaldo Cruz. Contas de saúde na perspectiva da contabilidade internacional : conta SHA para o Brasil, 2015 a 2019. Ministério da Saúde, Fundação Oswaldo Cruz, Instituto de Pesquisa Econômica Aplicada. Brasília: IPEA; 2022.
Ivama-Brummell AM, Wagner AK, Pepe VLE, et al. Ultraexpensive gene therapies, industry interests and the right to health: the case of onasemnogene abeparvovec in Brazil. Br Med J Glob Heal. 2022;(0:e008637):1–5. DOI: 10.1136/bmjgh-2022-008637.
Brasil. Câmara de Regulação do Mercado de Medicamentos. Secretaria Executiva. Anuário Estatístico do Mercado Farmacêutico 2019/2020. Brasília, DF; 2021.
Brasil. Ministério da Economia. Consulta Pública SEAE no 02/2021 - Critérios para precificação de medicamentos. Governo Federal - Participa + Brasil. Accessed on: 7 Nov 2021. Available in: https://www.gov.br/participamaisbrasil/consulta-publica-seae-n-02-2021-criterios-para-precificacao-de-medicamentos.
How to Cite
Copyright (c) 2022 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The authors hereby transfer, assign, or otherwise convey to RBFHSS: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print republish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to RHFHSS with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
This journal permits and encourages authors to post and archive the final pdf of the articles submitted to the journal on personal websites or institutional repositories after publication, while providing bibliographic details that credit its publication in this journal.